IS5329A - Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar - Google Patents

Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Info

Publication number
IS5329A
IS5329A IS5329A IS5329A IS5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A
Authority
IS
Iceland
Prior art keywords
adjuvant
monoglyceride
transport system
antigen
antigen transport
Prior art date
Application number
IS5329A
Other languages
English (en)
Inventor
Gizurarson Sveinbjörn
Guthmundsdottir Vera
Original Assignee
Lyfjathroun Hf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun Hf. filed Critical Lyfjathroun Hf.
Publication of IS5329A publication Critical patent/IS5329A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
IS5329A 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar IS5329A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
PCT/IS1998/000006 WO1999002186A2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant

Publications (1)

Publication Number Publication Date
IS5329A true IS5329A (is) 1999-12-29

Family

ID=36699745

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
IS5329A IS5329A (is) 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni

Country Status (13)

Country Link
US (2) US6514503B1 (is)
EP (1) EP1003551B1 (is)
JP (1) JP2001509491A (is)
KR (1) KR20010021622A (is)
CN (1) CN1202863C (is)
AT (1) ATE329617T1 (is)
AU (1) AU745849B2 (is)
BR (1) BR9810568A (is)
CA (1) CA2295237A1 (is)
DE (1) DE69834921T2 (is)
ES (1) ES2267189T3 (is)
IS (2) IS4518A (is)
WO (1) WO1999002186A2 (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
DK1075276T3 (da) * 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
IL146382A0 (en) 1999-05-13 2002-07-25 American Cyanamid Co Adjuvant combination formulations
EP1212086B8 (en) * 1999-08-18 2008-01-02 Industry-Academic Cooperation Foundation, The Catholic University of Korea Immunological tolerance-induction agent
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB0007465D0 (en) * 2000-03-29 2000-05-17 Amersham Pharm Biotech Uk Ltd Substrate for a lipase enzyme assay
AU7003101A (en) * 2000-06-22 2002-01-02 American Cyanamid Co Qs-21 and il-12 as an adjuvant combination
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
AU2002322380B2 (en) * 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002333194B2 (en) * 2001-08-16 2006-05-04 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
ATE424815T1 (de) * 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
JP2005519075A (ja) * 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
WO2003070272A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf, Biopharmaceutical Research An immunological adjuvant
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
EP1566621A4 (en) * 2002-11-21 2010-04-07 Sapporo Immuno Diagnostic Lab INSTRUMENT FOR COLLECTING AND RECOVERING STORAGE
CA2510199A1 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US20060264505A1 (en) * 2003-11-07 2006-11-23 Stiefel Laboratories, Inc. Dermatological compositions
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
KR101289649B1 (ko) * 2003-11-10 2013-08-09 유에이비 리서치 파운데이션 세균의 운반 및 ｃｎｓ 침입을 감소시키기 위한 조성물 및이를 이용한 방법
WO2007015441A1 (ja) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよび製剤
EP2059807B1 (en) * 2006-08-17 2013-02-20 The UAB Research Foundation Diagnosing pneumococcal pneumonia
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
EP2164957B1 (en) 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
AU2009302111A1 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2010105047A2 (en) * 2009-03-11 2010-09-16 Monsanto Technology Llc Herbicidal formulations comprising glyphosate and alkoxylated glycerides
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6114401B2 (ja) 2013-10-31 2017-04-12 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
BE545978A (is) 1955-03-11
FR2253499B1 (is) 1973-12-10 1977-11-04 Fabre Sa Pierre
US4420484A (en) 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS60149510A (ja) 1984-01-13 1985-08-07 Kao Corp 農薬組成物
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4771571A (en) 1986-12-31 1988-09-20 Nabisco Brands, Inc. Method for treating pineapple to prevent pineapple fruit diseases
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
DE69233069T2 (de) * 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
WO1994008604A1 (en) 1992-10-16 1994-04-28 Affinity Biotech, Inc. Convertible microemulsion formulations
CA2108266C (en) * 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
GB9207799D0 (en) * 1992-04-09 1992-05-27 Procter & Gamble Aqueous compositions
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
WO1994016061A1 (en) 1993-01-15 1994-07-21 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP3901213B2 (ja) * 1994-08-05 2007-04-04 インファルマ・ソシエテ・アノニム ホスファチジルコリンとプロスタグランジンｅ１及び／又はトロキサールチンとの複合体を含有する、勃起不能の局所治療のための製剤
FR2729307B1 (fr) * 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US5744137A (en) 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
CA2223768A1 (en) * 1995-06-09 1996-12-27 R.P. Scherer Corporation Suspension and soft gelatin capsules containing particulate matter
EP0781559B1 (en) 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
EP1003551A2 (en) 2000-05-31
US6514503B1 (en) 2003-02-04
AU8459898A (en) 1999-02-08
EP1003551B1 (en) 2006-06-14
AU745849B2 (en) 2002-04-11
WO1999002186A3 (en) 1999-04-01
ES2267189T3 (es) 2007-03-01
CA2295237A1 (en) 1999-01-21
KR20010021622A (ko) 2001-03-15
ATE329617T1 (de) 2006-07-15
DE69834921T2 (de) 2007-01-18
JP2001509491A (ja) 2001-07-24
IS4518A (is) 1999-01-10
DE69834921D1 (de) 2006-07-27
CN1262626A (zh) 2000-08-09
CN1202863C (zh) 2005-05-25
BR9810568A (pt) 2000-09-19
WO1999002186A2 (en) 1999-01-21
US20030099659A1 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
GB9808327D0 (en) Antidiotypic compounds
BG101995A (en) Saponin and sterol-containing vaccines
WO1999066879A3 (en) Systemic immune activation method using nucleic acid-lipid complexes
AU1593001A (en) Recombinant gelatin in vaccines
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AR025750A1 (es) Vacunas
DZ2462A1 (fr) Vaccin antigrippal.
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
NO982497L (no) Vaksine-sammensetninger for inntak gjennom nesen
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
NZ508366A (en) Neisseria meningitidis antigens and compositions
WO2001021207A3 (en) Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
SE9600647D0 (sv) Ny användning
EP2275128A3 (en) Protein-based streptococcus pneumoniae vaccines
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
EA199900069A1 (ru) Вакцинная композиция против малярии
FI934133A7 (fi) gp160:n johdannaiset ja gp160:een tai sen johdannaiseen perustuvat rok otteet, jotka sisältävät apuainetta
CY1107322T1 (el) Συνδυασμενο εμβολιο κατα της hπατιτιδας α και ηπατιτιδας β
ATE346931T1 (de) Clostridium perfringens impfstoff
HRP20080612T3 (hr) Kombinacija tenofovira, ritonavira i tmc114
CO5280140A1 (es) Antigeno (c42) asociado a tumores